Gin H, Nivet A M, Morlat P, Aubertin J
Clinique Médicale et des Maladies Infectieuses, Hôpital Pellegrin, Bordeaux.
Diabete Metab. 1989 Sep-Oct;15(5):247-50.
The action of a new semi-synthetic insulin preparation (30% soluble, 70% NPH insulin from Organon Laboratories Eragny sur Epte France) was studied in 6 healthy male volunteers using the euglycemic clamp technique (Biostator GCIIS) and compared with another 30/70 NPH (Actraphane Novo). Insulin levels, inhibition of C peptide secretion and glucose consumption were determined. There was a time lag between the maximum glucose need (167 +/- 18 mg/Kg/15 min at the 195th minute after the injection) and the peak plasma insulin level (98.3 +/- 8.5 uu/ml at the 105th minute following the injection). The maximum glucose need was followed by a slow fall in insulin levels with a duration of action of 17 hours. The total glucose need was the same as for Actraphane, although Actraphane had a slower action with a lower peak glucose need (144 +/- 18 mg/Kg/15 min at the 280th minute after injection). The two preparations had the same duration of action.
采用正常血糖钳夹技术(Biostator GCIIS),在6名健康男性志愿者身上研究了一种新型半合成胰岛素制剂(30%可溶性胰岛素,70%来自法国埃普特河畔埃拉尼的欧加农实验室的中效胰岛素)的作用,并与另一种30/70中效胰岛素(诺和灵N)进行了比较。测定了胰岛素水平、C肽分泌抑制和葡萄糖消耗情况。最大葡萄糖需求量(注射后第195分钟时为167±18mg/Kg/15分钟)与血浆胰岛素峰值水平(注射后第105分钟时为98.3±8.5uu/ml)之间存在时间延迟。最大葡萄糖需求量出现后,胰岛素水平缓慢下降,作用持续时间为17小时。尽管诺和灵N起效较慢,最大葡萄糖需求量较低(注射后第280分钟时为144±18mg/Kg/15分钟),但两种制剂的总葡萄糖需求量相同。两种制剂的作用持续时间相同。